vorinostat CTCL
Selected indexed studies
- Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. (Biologics, 2007) [PMID:19707308]
- Targeting histone deacetylases in T-cell lymphoma. (Leuk Lymphoma, 2017) [PMID:27813438]
- Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome. (Blood, 2024) [PMID:38170178]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. (2010) pubmed
- Targeting histone deacetylases in T-cell lymphoma. (2017) pubmed
- Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome. (2024) pubmed
- Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. (2007) pubmed
- Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. (2007) pubmed
- Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. (2025) pubmed
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). (2007) pubmed
- Vorinostat in cutaneous T-cell lymphoma. (2007) pubmed
- HDAC inhibitors: Promising agents for leukemia treatment. (2023) pubmed
- Differential Response of Mycosis Fungoides Cells to Vorinostat. (2023) pubmed